Tag Archives: Tufts Center for the Study of Drug Development

Social Media Raise Concerns for Marketers, Trial Sponsors

While biopharmaceutical companies are using websites and third-party postings to provide information on medical products — despite a host of regulatory issues — social media use is in its infancy related to the design and conduct of clinical trials. A recent report from the Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) finds that […]
Posted in FDA, Regulatory, social media | Also tagged , , , , | Leave a comment

Pharma Must Adopt New Development Paradigms, Says Tufts Report

Change has never been the word most associated with pharma. Irrespective of a record-breaking number of newly approved drugs over the last two years, a new report just out warns that continued growth is not sustainable unless R&D efficacies at drug companies are addressed and new paradigms adopted. As clinical trials continue to improve their […]
Posted in R&D, Strategy | Also tagged , | Leave a comment

Paring the Fat in Clinical Trials

Is too much irrelevant data slogging the pace to registration? Conclusions of a Pharm Exec May 15 Roundtable on finding ways to build efficiencies into an increasingly costly and complex clinical trials process have been bolstered by new research from the Tufts Center for the Study of Drug Development. Based on extensive survey data drawn […]
Posted in Op-Ed, R&D | Also tagged | 3 Comments

Talkback from Tufts: Defending R&D Costs

by Joe DiMasi, director of economic analysis, Tufts Center for the Study of Drug Development William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.  Both the posting and the working paper by F.M. Scherer on which the posting was […]
Posted in Guest Blog, pricing, R&D | Also tagged , | 2 Comments

Calculating the Cost of R&D: Defending Tufts Research

Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues,  because if you cannot justify your costs how do you expect to prevail on price?   
Posted in Op-Ed, pricing, R&D | Also tagged , , , , | 1 Comment
  • Categories

  • Meta